mani
protein
unbound
structur
lack
surfac
pocket
appropri
size
drug
bind
henc
varieti
experiment
comput
tool
develop
identif
cryptic
site
evid
unbound
protein
form
upon
ligand
bind
provid
tractabl
drug
target
site
goal
review
discuss
definit
detect
druggabl
site
potenti
valu
drug
discoveri
novel
method
base
molecular
dynam
simul
particularli
promis
yield
larg
number
transient
pocket
shown
minor
site
gener
capabl
bind
ligand
substanti
affin
base
recent
studi
current
methodolog
improv
combin
molecular
dynam
fragment
dock
machin
learn
approach
mani
protein
smallmolecul
bind
pocket
easili
detect
ligandfre
structur
cryptic
site
requir
conform
chang
becom
appar
cryptic
site
therefor
defin
site
form
pocket
ligandbound
structur
unbound
protein
structur
long
wellknown
protein
dynam
object
bind
site
may
chang
conform
upon
ligand
bind
howev
find
util
cryptic
hidden
bind
site
receiv
grow
attent
last
year
seemingli
motiv
two
factor
first
mani
biolog
relev
drug
target
lack
appropri
size
pocket
unbound
structur
support
strong
bind
drugsiz
ligand
suggest
cryptic
site
provid
previous
undescrib
pocket
potenti
enabl
target
protein
would
otherwis
consid
undrugg
therebi
expand
druggabl
genom
keep
idea
pocket
bind
small
molecul
inhibitor
proteinprotein
interact
class
includ
mani
challeng
target
cryptic
cryptic
site
locat
away
main
function
site
protein
modul
activ
protein
alloster
also
potenti
use
particularli
main
function
site
target
suffici
specif
target
distal
site
also
potenti
give
differ
pharmacolog
profil
second
factor
contribut
increas
interest
cryptic
site
avail
improv
methodolog
identifi
site
particularli
molecular
dynam
markov
state
simul
method
comput
feasibl
special
comput
tool
also
develop
integr
molecular
dynam
simul
fragment
dock
machin
learn
approach
despit
high
level
recent
interest
cryptic
site
review
recent
public
suggest
number
question
concern
definit
identif
druggabl
cryptic
site
potenti
valu
drug
discoveri
either
fulli
answer
answer
conflict
way
identifi
discuss
question
emphasi
problem
area
need
work
score
reflect
put
capac
pocket
bind
small
molecul
averag
fpocket
residu
druggabl
score
concav
residu
score
residu
within
ligand
form
pocket
score
valu
zero
pocket
wellform
bind
site
composit
measur
primarili
depend
volum
pocket
also
includ
factor
residu
polar
evolutionari
conserv
cryptic
site
defin
site
averag
pocket
score
less
unbound
form
protein
greater
bound
form
use
criteria
togeth
manual
inspect
cimermanc
et
al
select
pair
unbound
structur
site
consid
cryptic
due
low
pocket
score
bound
structur
function
relev
ligand
bound
site
result
cryptosit
set
use
test
cryptic
site
predict
algorithm
definit
cryptic
site
author
develop
could
provid
basi
commun
standard
group
test
newli
develop
method
potenti
issu
approach
cimermanc
et
al
determin
whether
site
correctli
consid
cryptic
import
consid
full
rang
conform
avail
protein
absenc
ligand
base
structur
comparison
singl
unbound
structur
ignor
ensembl
conform
avail
unbound
protein
especi
import
mobil
region
potenti
cryptic
site
consider
rais
follow
question
site
properli
consid
cryptic
absent
one
unbound
structur
even
fulli
form
unbound
structur
behavior
suggest
although
protein
adopt
conform
pocket
absent
also
access
conform
pocket
present
case
boundlik
conform
may
even
repres
abund
state
protein
absenc
ligand
altern
stringent
definit
pocket
consid
cryptic
absent
nearli
unbound
structur
protein
reliabl
identifi
absenc
bound
ligand
like
exist
larg
fraction
conform
state
avail
unbound
protein
beglov
et
al
number
addit
unbound
structur
vari
zero
per
protein
result
extend
cryptosit
dataset
includ
structur
rather
origin
inclus
addit
unbound
structur
reveal
boundlik
pocket
least
partial
form
unbound
structur
close
protein
cryptosit
set
exampl
origin
cryptosit
set
proteas
betasecretas
repres
unbound
bound
structur
unbound
structur
low
fpocket
druggabl
score
loop
compris
residu
far
activ
site
make
pocket
open
score
druggabl
figur
loop
close
inhibitor
bound
structur
result
wellform
pocket
bind
isophthalamid
ligand
high
affin
analysi
structur
unbound
extend
cryptosit
set
reveal
structur
pocket
question
almost
evenli
distribut
conform
resembl
unbound
bound
form
druggabl
score
vari
figur
thu
arguabl
whether
site
consid
cryptic
mani
protein
analysi
structur
extend
cryptosit
set
reveal
degre
spontan
shift
toward
ligandbound
conform
bind
site
distribut
observ
conform
heavili
weight
toward
unbound
state
exampl
origin
cryptosit
set
includ
unboundbound
pair
structur
campdepend
protein
kinas
known
protein
kinas
pka
unbound
structur
activ
loop
sequenc
sfg
rather
dfg
segment
seen
mani
kinas
protrud
activ
site
close
pocket
figur
site
open
inhibitor
bind
pdb
id
see
figur
except
unbound
structur
sfg
loop
resid
partial
hydrophob
outer
region
kinas
activ
site
figur
although
pocket
fulli
form
structur
structur
also
contain
bound
alloster
modul
far
activ
site
exampl
myristol
acid
structur
thu
probabl
reason
consid
pka
pocket
cryptic
protein
cryptic
site
complet
miss
unbound
structur
seem
rare
classic
exampl
type
tem
blactamas
elong
cryptic
site
discov
serendipit
crystal
reveal
two
small
molecul
crystal
buffer
bound
helic
bound
structur
pdb
code
posit
shorter
helix
shift
open
substanti
crevic
figur
howev
open
site
seen
unbound
structur
engin
variant
protein
exist
helix
unfold
result
partial
pocket
open
wildtyp
enzym
site
definit
cryptic
conclus
whether
site
cryptic
may
also
depend
resolut
avail
structur
exampl
protein
tyrosin
phosphatas
cryptic
alloster
site
close
cterminu
unbound
structur
resolut
respect
wellresolv
ctermin
helix
cover
alloster
site
render
undetect
current
pocket
detect
algorithm
howev
ctermin
region
flexibl
fact
helix
miss
sever
low
resolut
unbound
structur
poorli
resolv
absent
helix
alloster
site
appear
access
ligand
problem
demonstr
concept
cryptic
site
may
difficult
rigor
defin
unless
criteria
select
ensembl
protein
structur
consid
first
specifi
import
practic
question
concern
cryptic
site
use
drug
discoveri
frequent
describ
term
druggabl
concept
use
number
differ
mean
follow
definit
hajduk
et
al
defin
protein
druggabl
capabl
bind
ligand
affin
high
enough
modul
biolog
activ
addit
convent
druglik
molecul
compli
lipinski
ruleoff
ligand
consid
includ
macrocycl
peptidomimet
compound
molecular
weight
exceed
da
nonetheless
potenti
good
druglik
properti
compound
frequent
target
protein
site
larg
highli
lipophil
highli
polar
flexibl
flat
featureless
protein
may
difficult
drug
consid
undrugg
would
lead
miss
potenti
import
target
note
definit
consid
biolog
signific
target
must
establish
independ
druggabl
kozakov
et
al
develop
druggabilti
condit
base
ftmap
comput
method
ftmap
distribut
small
organ
probe
molecul
differ
size
shape
polar
surfac
protein
studi
find
favor
posit
probe
type
cluster
probe
rank
cluster
basi
averag
energi
region
bind
sever
differ
probe
cluster
call
consensu
site
predict
bind
energi
hot
spot
ftmap
avail
free
server
shown
extens
benchmark
experiment
data
bind
site
potenti
druggabl
harbor
bind
energi
hot
spot
strong
enough
compris
least
ftmap
probe
cluster
evalu
druggabl
cryptic
site
cryptosit
set
beglov
et
al
appli
ftmap
unbound
bound
structur
extend
set
accord
result
protein
least
one
unbound
structur
hot
spot
probe
cluster
within
cryptic
site
thu
site
predict
druggabl
even
protein
unbound
conform
exampl
cryptic
site
unbound
structur
pka
hot
spot
contain
probe
cluster
respect
howev
note
condit
bind
probe
cluster
impli
druggabl
base
analysi
tradit
drug
target
may
overpredict
druggabl
appli
cryptic
site
particular
found
cryptic
site
open
movement
side
chain
gener
low
affinitiesin
micromolar
rang
best
report
ligandseven
ftmap
show
site
contain
hot
spot
compris
probe
cluster
work
requir
establish
reliabl
druggabl
criteria
cryptic
site
mani
site
definit
druggabl
shown
bind
druglik
ligand
high
affin
tabl
e
shortest
distanc
atom
protein
atom
ligand
bound
structur
f
maximum
shortest
distanc
atom
protein
atom
ligand
superimpos
bound
structur
maxim
unbound
structur
distanc
less
distanc
previou
column
ligand
would
clash
protein
unbound
structur
thu
pocket
form
without
ligand
bind
g
type
bind
site
allo
alloster
ortho
orthoster
primari
bind
ppi
proteinprotein
interact
inhibitor
report
protein
therefor
reason
consid
druggabl
assur
analysi
captur
site
genuin
cryptic
even
unbound
structur
consid
protein
subject
test
ensur
avail
unbound
structur
would
clash
ligand
thu
pocket
fulli
form
upon
ligand
bind
condit
elimin
pka
inde
protein
unbound
structur
would
clash
superimpos
ligand
eight
site
shown
tabl
alloster
sinc
molecular
mechan
alloster
commun
root
dynam
natur
protein
alloster
modul
frequent
bind
flexibl
region
without
preform
pocket
alloster
site
becom
increasingli
import
drug
discoveri
henc
potenti
allosteri
prime
motiv
analysi
cryptic
site
tabl
also
show
nine
orthoster
primari
bind
site
five
enzym
activ
site
singlechain
enzym
activ
site
larg
cleft
alreadi
present
unbound
structur
howev
case
enzym
function
requir
high
level
flexibl
unbound
structur
site
may
fulli
open
exampl
staphylococc
nucleas
perform
rel
nonspecif
cleavag
nucleic
acid
thu
must
abl
adapt
differ
substrat
ligand
bind
dxp
reductoisomeras
lead
domain
motion
close
flexibl
loop
serv
lid
shield
content
activ
site
bulk
solvent
shown
enzym
lidgat
activ
site
must
oper
induc
fit
mechan
glutam
racemas
moonlight
enzym
serv
two
distinct
function
sarscov
main
proteas
cleav
two
differ
peptid
serotonin
nacetyltransferas
catalyz
acetyl
transfer
divers
array
tryptamin
analog
thu
abil
bind
sever
substrat
exclud
bulk
water
activ
site
seem
requir
substanti
flexibl
render
site
close
unbound
structur
last
two
item
tabl
repres
bind
site
small
molecul
inhibitor
proteinprotein
interact
target
class
increas
import
site
protein
target
frequent
bind
peptid
fragment
protein
partner
henc
open
certain
degre
howev
enabl
small
molecul
compet
protein
bind
may
requir
expans
pocket
region
consid
cryptic
exampl
well
known
cryptic
site
unbound
structur
alreadi
shallow
nonpolar
pocket
region
interact
chain
receptor
pocket
bind
small
molecul
moder
affin
howev
polar
extens
pocket
open
longer
much
higher
affin
inhibitor
bind
similar
case
seen
kra
small
pocket
sosbind
interfac
capabl
bind
weak
inhibitor
howev
bind
slightli
higher
affin
inhibitor
open
second
pocket
nearbi
open
addit
site
larger
ligand
limit
proteinprotein
interfac
exampl
protein
methyltransferas
expans
inhibitor
structur
reveal
addit
bind
site
visibl
even
samsah
bound
structur
thu
predict
potenti
expans
exist
pocket
bind
larger
ligand
interest
larg
unsolv
problem
lead
gener
concept
cryptic
site
earliest
report
cryptic
site
found
serendip
detect
distalsit
bind
small
molecul
mani
compon
crystal
buffer
bound
adventiti
target
identif
cryptic
site
tradit
involv
screen
librari
small
molecul
fragment
sitedirect
tether
use
antibodi
experiment
approach
requir
substanti
effort
frequent
neg
outcom
henc
recent
develop
comput
approach
potenti
import
bowman
geissler
demonstr
markov
state
model
built
hundr
microsecond
molecular
dynam
md
simul
identifi
prospect
cryptic
site
particular
result
show
known
cryptic
site
tem
blactamas
least
partial
open
simul
time
make
access
transient
pocket
detect
protein
author
argu
site
seen
unbound
crystal
structur
close
conform
also
promin
state
like
stabil
crystal
pack
recent
bowman
group
design
test
alloster
modul
bind
alloster
site
tem
blactamas
although
identifi
one
inhibitor
two
activ
compound
modest
effect
tem
activ
appli
markov
state
method
tem
blactamas
bowman
geissler
also
report
around
addit
pocket
open
like
access
time
site
distribut
across
surfac
protein
propos
provid
viabl
drug
target
site
result
without
controversi
oleinikova
et
al
also
perform
md
simul
three
protein
includ
tem
blactamas
found
run
start
protein
open
ie
bound
conform
without
ligand
present
pocket
promptli
close
howev
observ
ad
fragment
size
molecul
probe
occasion
caus
reopen
cryptic
site
mixedsolv
md
simul
includ
small
molecul
benzen
isopropanol
addit
water
also
use
group
find
cryptic
site
noth
declar
lu
ji
ni
zhang
j
discoveri
hidden
alloster
site
novel
target
alloster
drug
design
drug
discov
today
recent
review
comput
experiment
approach
identifi
hidden
alloster
site
protein
focu
exampl
success
use
techniqu
suggest
discoveri
hidden
alloster
site
offer
new
avenu
facilit
drug
design
greatli
expand
repertoir
avail
drug
target
contribut
search
alloster
drug
treatment
human
diseas
target
discuss
gpcr
receptor
tem
blactamas
hardi
beglov
hall
dr
wakefield
ae
luo
l
allen
kn
kozakov
whitti
vajda
explor
structur
origin
cryptic
site
protein
proc
natl
acad
sci
u
protein
benchmark
set
collect
cryptosit
paper
studi
use
comput
hot
spot
identif
tool
ftmap
result
show
ligandfre
structur
cryptic
site
potenti
drug
target
gener
strong
bind
energi
hot
spot
close
sinc
protein
hot
spot
limit
number
transit
pocket
open
markov
state
method
would
abl
bind
small
molecul
appropri
affin
limit
contradict
optimist
predict
concern
import
pocket
drug
discoveri
horn
jr
shoichet
bk
alloster
inhibit
core
disrupt
j
mol
biol
